<DOC>
	<DOCNO>NCT01664637</DOCNO>
	<brief_summary>The purpose study test safety effectiveness 10 mg TZP-102 give prior meal three time day compare placebo ( capsule look like active study drug contains active drug ) , administer 12 week , diabetic subject symptom associate gastroparesis .</brief_summary>
	<brief_title>Diabetic Gastroparesis Efficacy/Safety Study TZP-102</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>18 80 year age inclusive Type 1 type 2 diabetes mellitus History symptom gastroparesis least 3 month lead Screening Visit Documented delay gastric empty Upper gastrointestinal obstruction rule endoscopy barium scan Concomitant medication must stable least 2 week lead Screening visit must maintain study . Females childbearing potential must negative serum pregnancy test use ( agree continue use throughout study ) acceptable form contraception Gastrectomy , bariatric surgery , fundoplication vagotomy/pyloroplasty Has plan endoscopic pyloric injection botulinum toxin within 6 month prior Screening Visit study NG , PEG PEJ feed tube inpatient hospitalization gastroparesis within 2 week prior Screening Visit Required parenteral nutrition treatment gastroparesis within 2 month prior Screening Visit Active gastric pacemaker within 3 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>diabetic gastroparesis</keyword>
	<keyword>delay gastric empty</keyword>
	<keyword>gastroparesis</keyword>
	<keyword>diabetes mellitus , Type 1</keyword>
	<keyword>diabetes mellitus , Type 2</keyword>
</DOC>